Adolescent idiopathic scoliosis (AIS) leads to three-dimensional spinal deformity during adolescence, causing deviations in the frontal, sagittal, and axial planes, impairing physical function, balance, and lumbopelvic rhythm. Individuals with AIS exhibit decreased trunk movement, muscle overactivation, increased energy expenditure, balance/gait disturbances, and abnormalities in proprioceptive/vestibular input; pressure center deviations increase in postural control. These changes negatively impact daily life, pain, and quality of life.
Although the literature has examined the relationships between AIS and muscle activation, range of motion, pelvic position, and gait/balance, the relationship between lumbopelvic rhythm changes and curve type/localization/severity, and its impact on postural control and quality of life, has not been investigated. This study aims to elucidate movement patterns by evaluating lumbopelvic rhythm in individuals with AIS and to guide clinical diagnosis/treatment.
Eligibility
Sex
FEMALE
Min age
10 Years
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Inclusion criteria for the AIS group:
* Individuals diagnosed with AIS,
* Aged between 10-18 years,
* Having a Cobb angle greater than 10°,
* Having a pain intensity \< 3,
* Volunteer individuals.
Exclusion Criteria:
* Male gender,
* Body mass index ≥30,
* Presence of additional pathologies affecting the lumbopelvic region (disc herniation, spondylolisthesis, hip dysplasia, rheumatic diseases, etc.),
* Chronic pain lasting longer than 3 months,
* Lower extremity length discrepancy \> 2 cm,
* Orthopedic or neurological problems affecting the lower or upper extremity,
* History of acute injury,
* History of spinal surgery,
* Individuals with vestibular pathology or severe balance disorders.
Primary outcome measure(s)
Lumbopelvic rhythm, — January 30, 2025 - October 8, 2026 An Inertial Measurement Unit (IMU) will be used to assess lumbopelvic rhythm
Postural control — January 30, 2025 - October 8, 2026 Postural control will be assessed using the Bertec Balance Check Screener™ strength platform (BP5050 Bertec Co., Columbus, OH, USA) (13).
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.